Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.56 |
| ▸ | MMP9 | P14780 | 11/20 | 0.56 |
| ▸ | MMP13 | P45452 | 8/20 | 0.56 |
| ▸ | MMP3 | P08254 | 5/20 | 0.56 |
| ▸ | MMP1 | P03956 | 4/20 | 0.56 |
| ▸ | MMP7 | P09237 | 4/20 | 0.56 |
| ▸ | EEF2K | O00418 | 3/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374552 | 0.83 | MMP13 (0.64) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL6500230 | 0.82 | MMP2 (0.61) | MMP2MMP9MMP13ADAMTS4 | |
| SCHEMBL383079 | 0.82 | MMP2 (0.61) | MMP2MMP9MMP13ADAMTS4 | |
| SCHEMBL7375346 | 0.81 | SLC1A3 (0.60) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL4041728 | 0.81 | TDP1 (0.63) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL7370003 | 0.81 | MMP2 (0.72) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL7337519 | 0.81 | TDP1 (0.63) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL8091793 | 0.81 | MMP2 (0.63) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL14608753 | 0.81 | MMP2 (0.53) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL3861153 | 0.81 | MMP2 (0.53) | MMP2MMP9MMP13MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051625-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | Du Pont Pharmaceuticals Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |